title: Endophthalmitis caused by Pseudomonas aeruginosa in Taiwan.
abstract: OBJECTIVE
  To investigate the clinical settings, treatment given, and visual outcomes for eyes with Pseudomonas aeruginosa endophthalmitis in Taiwan.
  
  
  METHODS
  This is a retrospective, noncomparative, consecutive case series. Medical records were reviewed in 72 eyes of 71 patients with culture-proven P. aeruginosa endophthalmitis between January 1997 and December 2007.
  
  
  RESULTS
  The clinical settings included keratitis/scleritis (44.4%), cataract surgery (15.3%), penetrating keratoplasty (13.9%), endogenous source (12.5%), trauma (6.9%), penetrating keratoplasty with cataract surgery (2.8%), trabeculectomy with cataract surgery (1.4%), trabeculectomy (1.4%), and secondary implant (1.4%). Initial visual acuity ranged from counting fingers to no light perception. Final visual acuity was better than 5/200 in 6 of 72 eyes (8.3%), 4/200 to hand motions in 4 eyes (5.6%), and light perception to no light perception in 62 eyes (86.1%). In vitro testing, the susceptibility patterns of organisms isolated were as follows: ceftazidime (100%), cefepime (100%), aztreonam (100%), imipenem (99%), amikacin (94%), and gentamicin (86%). Five of 16 eyes (31.3%) that underwent primary or secondary pars plana vitrectomy with intravitreal antibiotics achieved a final visual acuity of 5/200 or better compared with 1 of 45 eyes (2.2%) treated with 1 or multiple vitreous tap(s) and intravitreal antibiotics (Fisher's exact test, P = 0.004).
  
  
  CONCLUSIONS
  Despite early diagnosis and treatment with intravitreal antibiotics, visual acuity outcomes were generally poor.
authors.affiliation: Department of Ophthalmology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kwei-Shan, Taoyuan, Taiwan.
authors.forename: Kuan-Jen
authors.initials: KJ
authors.lastname: Chen
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Sun
authors.forename: Chi-Chun
authors.initials: CC
authors.lastname: Lai
authors.forename: Wei-Chi
authors.initials: WC
authors.lastname: Wu
authors.forename: Tun-Lu
authors.initials: TL
authors.lastname: Chen
authors.forename: Ya-Hui
authors.initials: YH
authors.lastname: Kuo
authors.forename: An-Ning
authors.initials: AN
authors.lastname: Chao
authors.forename: Yih-Shiou
authors.initials: YS
authors.lastname: Hwang
authors.forename: Yen-Po
authors.initials: YP
authors.lastname: Chen
authors.forename: Nan-Kai
authors.initials: NK
authors.lastname: Wang
authors.forename: Laura
authors.initials: L
authors.lastname: Liu
authors.forename: Jane Zea-Chin
authors.initials: JZ
authors.lastname: Kuo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002387:Cataract Extraction; D003320:Corneal Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D009877:Endophthalmitis / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D015948:Keratoplasty, Penetrating; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*; D012189:Retrospective Studies; D015423:Scleritis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D013624:Taiwan; D014130:Trabeculectomy; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents